Pfizer
FDA approves Pfizer cancer drug Inlyta
January 30, 2012Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma
Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …
Pfizer pulls plug on Alzheimer’s drug
January 18, 2012Research and Development, Sales and Marketing Medivation, Pfizer, dimebon
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …
NantWorks to invest $85.5m in former Pfizer plant
January 16, 2012Manufacturing and Production Exubera, Nantworks, Pfizer
A former Pfizer manufacturing facility in Indiana, US, looks set for a new lease of life after technology company NantWorks …
Pharma unprepared for annus horribilis
January 12, 2012Research and Development, Sales and Marketing AZ, Pfizer, Takeda, patents, pharma
A new survey shows pharma is not prepared to deal with the tough year ahead as many blockbuster drugs begin …
Merck facility reborn as science park
January 11, 2012Research and Development BioCity, MSD, Merck, Newhouse, Pfizer, Roslin BioCentre, Scotland
A former Merck research site in Scotland has been given a new lease of life as a biotech science park. …
Crisis in the boardroom: 2011’s most dramatic departures
January 11, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, KV pharmaceuticals, Kindler, Pfizer, management
In December 2010, Jeffrey Kindler, the chief executive of Pfizer suddenly announced his departure from the company.His abrupt exit made …
Keep prescribing Lipitor – the generics are nearly here, says Pfizer
January 5, 2012Medical Communications, Sales and Marketing Lipitor, NHS, Pfizer, statin prescribing
Pfizer has launched a campaign to persuade UK doctors to keep prescribing Lipitor ahead of its patent expiry in May. …
FDA accepts Pfizer’s arthritis pill for review
December 22, 2011Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …
Ian Read elected as chairman of the board at Pfizer
December 13, 2011Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Ian Read, Kindler, Pfizer
Pfizer’s chief executive and president Ian Read has been elected as the firm’s new chairman. Read succeeds George Lorch as …
Pfizer awaits verdict on contaminated site clean-up plan
December 13, 2011Manufacturing and Production, Sales and Marketing FDA, Pfizer, manufacturing
The US Environmental Protection Agency is due to deliver a verdict on a $205 million proposal by Pfizer to clean …
Big pharma: big rewards come from big risks
December 5, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, R&D productivity
John LaMattina joined Pfizer in 1977 after having completed his PhD in organic chemistry, and moved up through the ranks …
Stroke crisis to hit UK unless government acts, warns report
December 5, 2011Sales and Marketing BMS, Pfizer, Pradaxa, UK, stroke
Major improvements are needed in the treatment of atrial fibrillation to avoid a UK stroke epidemic, according to a new …
Teva gains tentative approval to sell generic Lipitor in 2012
December 5, 2011Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
Teva has gained a tentative approval by the FDA to sell its generic form of Pfizer’s blockbuster statin Lipitor next …
FDA approves Ranbaxy’s generic Lipitor
December 1, 2011Manufacturing and Production, Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
The FDA will allow Ranbaxy to develop a generic version of Pfizer’s blockbuster statin Lipitor. The firm has received final …
Watson launches first generic Lipitor in US
November 30, 2011Sales and Marketing Lipitor, Pfizer, Watson, atorvastin
Watson Pharmaceuticals has launched its generic version of Pfizer’s blockbuster statin Lipitor as the drug goes off patent in the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
